文献速递创伤骨科关节外科骨质疏松与代谢性骨病

CD177、MYBL2和RRM2是肌肉骨骼感染的潜在生物标志物

CD177, MYBL2, and RRM2 Are Potential Biomarkers for Musculoskeletal Infections.
PubMed 文献 · Clin Orthop Relat Res · 2025-02-06

该研究纳入19例急性肌肉骨骼感染患者和21例无感染对照,检测血清和PBMC中CD177、MYBL2、RRM2的蛋白浓度;三种标志物在感染组均高于对照组,且7例临床治愈患者治疗后水平下降;ROC曲线下面积多数大于0.99,作者认为可能有助于诊断和监测治疗反应,但需大规模临床研究确认。

要点

  • 肌肉骨骼感染组血清和PBMC中CD177、MYBL2、RRM2蛋白浓度均高于对照组(p<0.01)。
  • 7例临床治愈患者治疗后血清和PBMC中三种标志物水平均下降(p≤0.02)。
  • 血清和PBMC中三种标志物诊断肌肉骨骼感染的ROC曲线下面积多数大于0.99。

核心结论

  • 作者认为可运用血液CD177、MYBL2、RRM2检测辅助诊断肌肉骨骼感染,尤其在关节穿刺或组织培养困难时,也可能辅助监测治疗反应。
  • 作者指出部分标志物可能在其他炎症状态下也升高,需大规模临床研究确认其区分肌肉骨骼感染与其他炎症的可靠性。

研究设计与样本

  • 2023年4月至2024年6月,26例有急性肌肉骨骼感染临床征象的患者中19例培养阳性者纳入感染组,另设21例无感染或全身炎症的择期足踝畸形矫正患者为对照组。
  • 采集血液样本,用qRT-PCR定量PBMC中CD177、MYBL2、RRM2的RNA转录水平,用酶联免疫吸附试验检测血清和PBMC蛋白浓度。
  • 对7例临床治愈的感染患者在8周随访时采集血样,比较治疗前后标志物水平。
  • 用受试者工作特征(ROC)曲线分析评估诊断准确性,采用非配对非参数t检验即Mann-Whitney检验进行比较。

主要发现

  • 血清CD177感染组中位数227(155至432) vs 对照组54(10至100),中位数差173,p<0.01;血清MYBL2 255(231至314) vs 180(148至214),中位数差75,p<0.01;血清RRM2 250(216至305) vs 190(148至255),中位数差60,p<0.01。
  • PBMC CD177感染组中位数55.3(39.1至80.5) vs 对照组17.5(10.5至27.5),中位数差37.8,p<0.01;PBMC MYBL2 144(114至190) vs 91(70至105),中位数差53,p<0.01;PBMC RRM2 168(143至202) vs 100(77.5至133),中位数差68,p<0.01。
  • 7例患者治疗后血清CD177 3080(2690至3320) vs 治疗前4250(3100至8640),中位数差1170,p<0.01;血清MYBL2 4340(4120至4750) vs 5010(4460至5880),中位数差670,p<0.01;血清RRM2 4350(3980至5000) vs 5025(4430至6280),中位数差675,p=0.01。
  • 7例患者治疗后PBMC CD177 805(680至980) vs 治疗前1025(750至1610),中位数差220,p<0.01;PBMC MYBL2 2300(2100至2550) vs 2680(2220至3400),中位数差380,p=0.02;PBMC RRM2 2720(2500至3200) vs 3350(2825至4030),中位数差630,p<0.01。

关键数值与推荐

  • 诊断肌肉骨骼感染的ROC曲线下面积95%CI:血清CD177 >0.99、PBMC CD177 >0.99;血清MYBL2 >0.99、PBMC MYBL2 >0.99;血清RRM2=0.96、PBMC RRM2 >0.99。

临床怎么用

  • 作者认为血液CD177、MYBL2、RRM2检测可能辅助诊断肌肉骨骼感染,尤其在关节穿刺或组织培养困难时。
  • 作者认为这些标志物也可能辅助监测治疗反应。

局限性

  • 作者指出部分标志物可能在其他炎症状态下也升高,需大规模临床研究确认其区分肌肉骨骼感染与其他炎症的可靠性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Biomarkers of infection are measurable indicators that reflect the presence of an infection in the body. They are particularly valuable for detecting infections and tracking treatment responses. Previous transcriptome analysis of peripheral blood mononuclear cells (PBMCs) collected from patients during the active phase of diabetic foot infection identified the upregulation of several genes, including a neutrophil-specific cell surface glycoprotein, CD177, an Myb-related transcription factor 2 (MYBL2), and ribonucleotide reductase regulatory subunit M2 (RRM2). We aimed to investigate whether these observations in diabetic foot infections could be extrapolated to other musculoskeletal infections. QUESTIONS/PURPOSES: (1) Are the protein concentrations of CD177, MYBL2, and RRM2 elevated in serum or PBMCs of patients with musculoskeletal infections? (2) Do serum and PBMC concentrations of CD177, MYBL2, and RRM2 decrease in response to antibiotic therapy? (3) Can these biomarkers give diagnostic accuracy and differentiate patients with musculoskeletal infections from controls? METHODS: From April 2023 to June 2024, we treated 26 patients presenting with clinical symptoms and signs of acute musculoskeletal infections, including elevated inflammatory markers (white blood cell [WBC] and C-reactive protein [CRP]) and local changes such as swelling, erythema, tenderness or pain, warmth, purulent drainage, sinus tract, or wound leading to bone or hardware. Diagnosis included periprosthetic joint infection (PJI), foot and ankle infection (FAI), fracture-related infection (FRI), and septic arthritis of the native joints. Patients with chronic recurrent osteomyelitis, PJI, or FRI were excluded from the study. Among the 26 patients deemed potentially eligible, 19% (5) were excluded for the following reasons: prison inmate (1), unable to provide consent because of severe sepsis (1), mental illness (1), and declined to participate (2). Of the 81% (21) of patients who provided consent, cultures from 9.5% (2) were negative. These two patients were ultimately diagnosed with inflammatory arthritis: gout (1) and rheumatoid arthritis (1); thus, the musculoskeletal infection group for analysis consisted of 73.1% (19 of 26) of patients. A control group of 21 patients undergoing elective foot or ankle deformity correction surgery without infections or systemic inflammation was included. Because foot or ankle deformity is highly unlikely to influence the immunologic profile of the subjects, we believed that these patients would serve as an appropriate control group. Other than the absence of infection and the lower prevalence of diabetes mellitus, the control group was comparable to the study group in terms of demographics and clinical factors, including age and sex distribution. We collected blood samples from both patients and controls and quantified CD177, MYBL2, and RRM2 RNA transcription levels in the PBMC using qRT-PCR. We also assessed protein concentrations in the serum and PBMC using an enzyme-linked immunosorbent assay. A comparative analysis of the three biomarkers was performed on 19 patients with musculoskeletal infections with positive cultures and 21 controls to assess their diagnostic potential using the unpaired nonparametric t-test with the Mann-Whitney test. We obtained 8-week follow-up blood samples from seven patients with musculoskeletal infections who clinically healed. Healing was defined by normalization of inflammatory markers (WBC and CRP) and absence of swelling, erythema, local tenderness or pain, warmth, purulent drainage, sinus tract, or open wound. We performed a comparative analysis of the seven patients during active infection and after treatment to determine a change in the level of CD177, MYBL2, and RRM2 in their serum and PBMCs. These findings were also compared with those of the control group. We evaluated the diagnostic accuracy of CD177, MYBL2, and RRM2 for musculoskeletal infections using receiver operating characteristic (ROC) curve analysis. RESULTS: The musculoskeletal infections group showed a larger increased serum and PBMC concentrations of CD177, MYBL2, and RRM2 proteins compared with the control group. The mean protein concentrations of CD177, MYBL2, and RRM2 were increased in the serum and PBMC of the musculoskeletal infections group compared with the controls. Serum levels of all biomarkers investigated were higher in musculoskeletal infections group compared with the control group (CD177 227 [155 to 432] versus 54 [10 to 100], difference of medians 173, p < 0.01; MYBL2 255 [231 to 314] versus 180 [148 to 214], difference of medians 75, p < 0.01; RRM2 250 [216 to 305] versus 190 [148 to 255], difference of medians 60, p < 0.01). Similarly, PBMC levels of all biomarkers were higher in the musculoskeletal infections group (CD177 55.3 [39.1 to 80.5] versus 17.5 [10.5 to 27.5], difference of medians 37.8, p < 0.01; MYBL2 144 [114 to 190] versus 91 [70 to 105], difference of medians 53, p < 0.01; RRM2 168 [143 to 202] versus 100 [77.5 to 133], difference of medians 68, p < 0.01). Additionally, serum levels of all biomarkers decreased in seven patients with musculoskeletal infections after infection treatment (CD177 3080 [2690 to 3320] versus 4250 [3100 to 8640], difference of medians 1170, p < 0.01; MYBL2 4340 [4120 to 4750] versus 5010 [4460 to 5880], difference of medians 670, p < 0.01; RRM2 4350 [3980 to 5000] versus 5025 [4430 to 6280], difference of medians 675, p = 0.01). Similarly, PBMC levels of all biomarkers were lower after infection treatment (CD177 805 [680 to 980] versus 1025 [750 to 1610], difference of medians 220, p < 0.01; MYBL2 2300 [2100 to 2550] versus 2680 [2220 to 3400], difference of medians 380, p = 0.02; RRM2 2720 [2500 to 3200] versus 3350 [2825 to 4030], difference of medians 630, p < 0.01). The area under the ROC curve for diagnosing musculoskeletal infections in the serum and PBMC was as follows: CD177 95% confidence interval [CI] > 0.99 and > 0.99, MYBL2 95% CI > 0.99 and > 0.99, and RRM2 95% CI = 0.96 and > 0.99, respectively. CONCLUSION: We may utilize blood-based tests for CD177, MYBL2, and RRM2 to aid in the diagnosis of musculoskeletal infections, particularly when arthrocentesis or obtaining tissue culture is challenging. They may also assist in monitoring treatment response. As some of these biomarkers may also be elevated in other inflammatory conditions, a large-scale clinical study is needed to confirm their reliability in differentiating musculoskeletal infections from other inflammatory conditions. CLINICAL RELEVANCE: CD177, MYBL2, and RRM2 proteins in blood samples may serve as novel biomarkers for diagnosing and monitoring treatment response in musculoskeletal infections.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Agidigbi TS, Fram B, Molloy I, et al. CD177, MYBL2, and RRM2 Are Potential Biomarkers for Musculoskeletal Infections. Clin Orthop Relat Res. 2025. PMID: 39915095. doi:10.1097/CORR.0000000000003402

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。